NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis $0.02 -0.01 (-33.33%) As of 10:00 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Vaxxinity Stock (NASDAQ:VAXX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxxinity alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.00▼$0.0552-Week Range$0.00▼$0.10Volume213 shsAverage Volume7,060 shsMarket Capitalization$2.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. Read More Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAXX Stock News HeadlinesBrain healthOctober 24, 2024 | newsweek.comNTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.August 26 at 2:00 AM | Banyan Hill Publishing (Ad)Vaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comSee More Headlines VAXX Stock Analysis - Frequently Asked Questions How have VAXX shares performed this year? Vaxxinity's stock was trading at $0.0050 at the beginning of 2025. Since then, VAXX stock has increased by 300.0% and is now trading at $0.02. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) issued its earnings results on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16). When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxxinity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxxinity investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Rivian Automotive (RIVN), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings3/27/2023Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VAXX CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees90Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book0.18Miscellaneous Outstanding Shares126,748,000Free Float45,553,000Market Cap$2.53 million OptionableNot Optionable Beta-24.16 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:VAXX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is hereTop analysts are calling the AI boom “an existential race” — and Washington is going all in. Trillions are bei...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.